Ironically, the medication that is currently causing the greatest scientific interest in human longevity has been kept in medicine cabinets since 1958. Metformin is a cheap, off-patent tablet that was first used to treat Type 2 diabetes and costs less than $1 per day. It doesn’t have stylish packaging. It’s not a Silicon Valley startup. However, the biology of aging is receiving more attention from researchers than nearly anything else in their field.
In general, the science is as follows: metformin seems to lower inflammation, enhance cell energy production, and possibly even replicate the biological effects of calorie restriction without the hunger. The medication has significantly increased lifespan in model organisms, such as the nematode C. elegans and specific mouse strains. That is not insignificant.
| Category | Details |
|---|---|
| Drug Name | Metformin (Biguanide class) |
| First Synthesized | 1922 (introduced for diabetes treatment in France, 1958) |
| Primary Use | First-line oral medication for Type 2 Diabetes Mellitus (T2DM) |
| Global Users | Over 150 million people worldwide (daily use) |
| Approximate Daily Cost | Less than $1 per day (off-patent, widely generic) |
| Key Anti-Aging Mechanism | Reduces inflammation, improves mitochondrial function, mimics caloric restriction, reduces oxidative stress |
| Major Clinical Trials | MILES (Metformin In Longevity Study), TAME (Targeting Aging with Metformin) |
| TAME Trial Target Group | Older adults with cancer, heart disease, or cognitive impairment |
| Notable Side Effects | GI issues (20–30% of users), potential Vitamin B12 deficiency (6–30% with chronic use), rare lactic acidosis |
| Current Anti-Aging Status | Not FDA-approved for aging; evidence promising but inconclusive — trials ongoing |
| Supporting Institution | American Federation for Aging Research (AFAR), NIH, Alzheimer’s Drug Discovery Foundation |
Naturally, results from animals don’t always apply to humans, but the consistency of those findings across species forced scientists to investigate further. Additionally, they discovered something unexpected when comparing the medical records of diabetic patients taking metformin to those taking other medications: in certain analyses, the metformin group seemed to outlive even non-diabetic people not taking the medication at all. It’s difficult to completely rule out the possibility that confounding factors contributed to the outcome.
A growing number of people have chosen not to wait for the clinical verdict, including Michael and Shari Cantor, a couple from West Hartford, Connecticut. They both take metformin and report feeling healthy and full of energy. They are both in their mid-60s. Shari started taking it during the pandemic after learning that it could prevent serious infections, while Michael started about ten years ago when his blood sugar was starting to rise. “We all want to live a little longer, high-quality life if we can,” Michael has stated. It’s the kind of anecdote that worries epidemiologists because firsthand accounts don’t qualify as proof, but it also reveals something about the cultural era we live in. There are no people waiting around.
Two significant trials have been conducted as the official scientific response to this interest. Early findings from the Metformin In Longevity Study, or MILES study, indicate that the medication may cause gene expression patterns linked to younger biological age. The more ambitious TAME trial, which stands for Targeting Aging with Metformin, is testing the medication in older adults who have been diagnosed with heart disease, cancer, or cognitive decline.
The logic is careful: rather than claiming metformin can make someone immortal, researchers are asking a narrower and arguably more meaningful question — can this drug delay the onset of additional age-related diseases and extend the period of life spent in reasonable health? That framing is important. It’s the difference between a slow decline and a fountain of youth, and for the majority of people, the latter may be the more realistic version of the dream.
Steven Austad, a senior scientific advisor at the American Federation for Aging Research, has put it plainly: “I don’t know if metformin increases lifespan in people, but the evidence that exists suggests that it very well might.” That’s the calibrated language of a scientist who is aware of how many promising compounds have failed in rigorous human trials; it’s not an endorsement. However, this kind of cautious optimism tends to advance research.
The potential benefits of metformin for individuals without pre-diabetes or diabetes are still unknown. Some researchers believe the drug’s anti-aging effects may be largely downstream of its glucose-lowering properties — that it helps healthy people primarily by preventing metabolic decline, not by some independent longevity mechanism. Some believe there may be more going on, perhaps related to its impact on the gut microbiome or its activation of AMPK, a cellular pathway associated with stress response and energy regulation. As of right now, the truth is that no one knows for sure. Even after 60 years of clinical use, the cellular mechanisms underlying metformin’s fundamental actions are still surprisingly unclear.
What makes this story genuinely unusual isn’t just the science — it’s the drug itself. A century-old compound, derived from a French wildflower called Galega officinalis used in folk medicine for centuries, now at the center of a serious scientific conversation about extending human healthspan. It has an almost literary quality. Watching this unfold over the past decade, it’s hard not to notice how much the most interesting medical discoveries tend to come not from billion-dollar pipelines but from older molecules being looked at with newer eyes.
